home / stock / cdtx / cdtx news

CDTX News and Press, Cidara Therapeutics Inc. From 06/29/20

Stock Information
Company Name: Cidara Therapeutics Inc.
Stock Symbol: CDTX
Market: NASDAQ
Website: cidara.com
Menu
CDTX CDTX Quote CDTX Short CDTX News CDTX Articles CDTX Message Board
Get CDTX Alerts

News, Short Squeeze, Breakout and More Instantly...
CDTX - Cidara Therapeutics Added to Russell 3000® Index

SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell ...
CDTX - Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

SAN DIEGO, June 23, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President a...

CDTX - Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President a...

CDTX - AstraZeneca's Lynparza Label Expansion, And Other News: The Good, Bad And Ugly Of Biopharma

AstraZeneca and Merck Receive Lynparza Boost AstraZeneca ( AZN ) and Merck & Co. ( MRK ) announced that their Lynparza has received the FDA nod for its fourth tumor type, prostate cancer. This PARP inhibitor is now authorized to be used for treating patients with previously treated m...
CDTX - Cidara commences pivotal study of lead drug rezafungin

The first patient has been dosed in a pivotal 462-subject Phase 3 clinical trial, ReSPECT , evaluating Cidara Therapeutics' ( CDTX +0.9% ) lead candidate rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. More...

CDTX - Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced ...

CDTX - Cidara Therapeutics EPS misses by $0.12, beats on revenue

Cidara Therapeutics (NASDAQ: CDTX ): Q1 GAAP EPS of -$0.46 misses by $0.12 . More news on: Cidara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CDTX - Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months e...

CDTX - Cidara Therapeutics (CDTX) Presents At Maxim Group Infectious Disease Virtual Conference - Slideshow

The following slide deck was published by Cidara Therapeutics, Inc. in conjunction with this Read more ...

CDTX - Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020  Phase 2 trial shows superiority of rezafungin in time to clear deadly infection Seven abstracts highlight new data on influenza antiviral conjugates (AVCs) from Cloudbreak® antiviral ...
Previous 10 Next 10